netFormulary NHS
Nottinghamshire Area Prescribing Committee
Joint Formulary
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
Chapter Links...
 Details...
10.01.03  Expand sub section  Drugs which suppress the rheumatic disease process
Baricitinib (Olumiant®)
(Rheumatology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Tablet

  • Nottinghamshire Treatment Centre and SFHT approved in line with NICE TA466 for moderate to severe rheumatoid arthritis
  • SFH - available for use in RECOVERY trial

Available through homecare for NUH patients. Please contact pharmacy medicines homecare team for further information

 
Link  MHRA Drug Safety Update 2020: Increased risk of diverticulitis
Link  NICE TA466:Baricitinib for moderate to severe rheumatoid arthritis
   
Sarilumab (Kevzara®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Injection


Nottingham NHS Treatment Centre and SFH only: Approved in accordance with: NICE TA485 for moderate to severe rheumatoid arthritis.

Available at NUH only:

  • Approved for treating adult patients admitted to Intensive and Acute Respiratory Care Units with severe COVID-19 pneumonia, in accordance with NHS Interim Clinical Commissioning Policy (Feb '21) - Unlicensed indication

 

Available through homecare for NUH patients. Please contact pharmacy medicines homecare team for further information

 
Link  NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
   
Tofacitinib citrate
(XELJANZ®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Tablets
Nottingham NHS Treatment Centre and SFH only: Approved in accordance with: NICE TA480 for moderate to severe rheumatoid arthritis.

Nottingham NHS Treatment Centre: Approved in accordance with: NICE TA543 for treating active psoriatic arthritis after inadequate response to DMARDs.

Nottingham NHS Treatment Centre and NUH: Approved in accordance with NICE TA547 for moderately to severely active ulcerative colitis

Available through homecare for NUH patients. Please contact pharmacy medicines homecare team for further information

 
Link  Link to reviews
Link  NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Link  NICE TA543:Tofacitinib for treating active psoriatic arthritis
Link  NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
   
Upadacitinib (Rinvoq®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

Tablets

Available at NUH only:

  • Approved in accordance with NICE TA665 for treating severe rheumatoid arthritis in adults
 
Link  NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
   
Filgotinib (Jyseleca®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

Tablet

Available at NUH only:

  • Approved in accordance with NICE TA676 for the treatment of moderate to severe rheumatoid arthritis in adults.
 
Link  NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
   
10.01.03  Expand sub section  Gold
10.01.03  Expand sub section  Penicillamine
10.01.03  Expand sub section  Antimalarials
10.01.03  Expand sub section  Drugs affecting the immune response to top
10.01.03  Expand sub section  Cytokine modulators
10.01.03  Expand sub section  Sulfasalazine
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Grey

Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.
Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a future APC meeting.
Grey / Non-Formulary (no formal assessment): APC has not formally reviewed this medicine or indication because it had never been requested for formulary inclusion. Often used for drugs new to market.
  

Red

Medicines which should normally be prescribed by specialists only. eg hospital only.
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
  

Amber 1

Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised.
Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the Nottinghamshire APC.
  

Amber 2

Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation.
A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust DTCs and approved by the Nottinghamshire APC.
*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice
  

Amber 3

Primary care/ non specialist may initiate as per APC guideline.
The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC(s) and approved by the Nottinghamshire APC.
  

Green

Medicines suitable for routine use within primary care.
Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.   

OTC

  

netFormulary